Turn Therapeutics Inc. (TTRX)
Nasdaq · Healthcare · Biotechnology
$12.36−7.28%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $375M
- 52-week range
- $2.57 – $26.50
- 52-week change
- +90.43%
- EPS (trailing)
- −$0.29
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$3.2M
- Diluted EPS
- −$0.12
From the company’s annual report on SEC EDGAR.
About Turn Therapeutics Inc.
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Headquarters: Westlake Village, United States · 2 employees · turntherapeutics.com